Sirolimus
- Generic Name
- Sirolimus
- Brand Names
- Fyarro, Hyftor, Rapamune
- Drug Type
- Small Molecule
- Chemical Formula
- C51H79NO13
- CAS Number
- 53123-88-9
- Unique Ingredient Identifier
- W36ZG6FT64
- Background
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria Streptomyces hygroscopicus, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive a...
- Indication
Sirolimus is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants. In patients at low-to moderate-immunologic risk, it is recommended that sirolimus be used initially in a regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn two to four months after transplantation. In pati...
- Associated Conditions
- Chordomas, Facial Angiofibroma, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Lymphangioleiomyomatosis (LAM), Renal Angiomyolipomas, Transplanted Organ Rejection, Metastatic malignant Perivascular Epithelioid Cell Neoplasms, Unresectable, locally advanced malignant Perivascular Epithelioid Cell Neoplasms
- Associated Therapies
- -
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
- Conditions
- Interventions
- Biological: Actinium Ac 225-DOTA-DaratumumabProcedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyBiological: DaratumumabProcedure: EchocardiographyDrug: FludarabineProcedure: Hematopoietic Cell TransplantationBiological: Indium In 111-DOTA-DaratumumabDrug: MelphalanProcedure: Multigated Acquisition ScanProcedure: Radionuclide ImagingProcedure: Single Photon Emission Computed TomographyDrug: SirolimusDrug: TacrolimusRadiation: Total Marrow and Lymphoid Irradiation
- First Posted Date
- 2024-03-01
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT06287944
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 6
- Registration Number
- NCT06279494
Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder
- First Posted Date
- 2024-02-15
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT06261060
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection Associated Chronic Conditions
- Conditions
- Interventions
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Simmaron Research Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06257420
- Locations
- 🇺🇸
The Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Center For Complex Diseases, Seattle, Washington, United States
🇺🇸Sierra Internal Medicine, Incline Village, Nevada, United States
The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus
- Conditions
- Interventions
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 276
- Registration Number
- NCT06236022
- Locations
- 🇨🇳
Tongji Hospital, Wuhan, Hubei, China
Hemorrhagic Brainstem Cavernous Malformations Treatment With Sirolimus: aSingle Centre, Randomized, Placebo-controlled Pilot Trial
- Conditions
- Interventions
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT06091332
- Locations
- 🇨🇳
Huashan Hospital, Fudan University, Shanghai, Shanghai, China
Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT06084780
- Locations
- 🇺🇸
Cleveland Clinic Digestive Disease & Surgery Institute (DDSI), Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Sirolimus for Improving Social Abilities in People With PTEN Germline Mutations
- Conditions
- Interventions
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Stanford University
- Registration Number
- NCT06080165
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Stanford University, Stanford, California, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
Advancing Transplantation Outcomes in Children
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-12-10
- Target Recruit Count
- 200
- Registration Number
- NCT06055608
- Locations
- 🇺🇸
University of Alabama at Birmingham (Site # 71038), Birmingham, Alabama, United States
🇺🇸Children's Hospital of Los Angeles (Site #: 71036), Los Angeles, California, United States
🇺🇸Cedars-Sinai Medical Center (Site #: 71026), Los Angeles, California, United States
Evaluating Rapamycin Treatment in Alzheimer's Disease Using Positron Emission Tomography
- First Posted Date
- 2023-09-01
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 15
- Registration Number
- NCT06022068
- Locations
- 🇸🇪
Karolinska University Hospital Memory clinic, Solna, Stockholm, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.